| ObjectivHeart failure(HF) is a threat to the safety of human life,one serious illness,acute and severe heart failure status of the high mortality rates has yet to be changed.Brain natriuretic peptide(BNP) is a major Ventricular muscle from the synthesis and secretion of peptide hormones,and are subject to assert and ventricular wall tension adjustment, in heart failure when compensatory increases to antagonize renin-angiotensin-aldoster-one system(SAAS) and the sympathetic nervous system(SNS),with expansion of arterio-venous blood vessels,diuretic,natriuretic,lower blood pressure,regulate the biological activity of ventricular remodeling and so on.Intravenous infusion of exogenous brain natriuretic peptide can play a role in improving the symptoms of heart failure.This study was addressed to patients with acute exacerbation of chronic HF intravenous infusion of recombinant human brain natriuretic peptide(rhBNP)(Xin Huo Su - Tibetan Medicine Bio-Pharmaceutical Co.,Ltd.Chengdu Nuodikang production), and in contrast with the traditional HF treatment,to explore new live prime clinical efficacy and safety.Materials and MethodsSelected in October 2007～April 2009 in the Cardiac Care Unit(CCU) of Shengjing Hospital of the Medical University of China with chronic HF treated 60 patients with acute exacerbation were randomly divided into treatment group and control group.In the standard treatment group on the basis of anti-heart failure therapy was added rhBNP(Xin Huo Su),after first giving the loading dose 1.5-2ug/kg, continuous infusion 0.0075-0.01ug/kg/min a total of 48 hours.All selected objects are to LVEF,LVEDD,BNP measurement,evaluation breathing difficulties and NYHA cardiac function classification on admission at treatment,7 days and followed up for 3 months. Application SPSS 13.0 statistical software for data statistical analysis,brain natriuretic peptide data showed a skewed distribution.After the natural logarithm transformed,the data showed the normal distribution. Measurement data with(?)+S said that the difference comparison between different time points was used to compare repeated measures analysis of variance.The comparison between groups at the same time point was usd an independent two-sample t test,the data of P＜0.05 are statistically significant.Results1.Treatment of 7 days,the BNP levels of the treatment group(1145.27±484.78 pg / ml) and dyspnea score(1.03±0.18) were significantly lower than admission levels (2621.93±885.34 pg / ml) /(3.53±0.49)(P＜0.001).The BNP levels of the treatment group were significantly lower than the control group(1594.24±478.10 pg / ml)(P＜0.05).The improvement score of the difficulty in breathing(2.47±0.63) was significantly higher than the control group(1.47±0.63)(P＜0.05).Compared with the seven days of treatment,the BNP levels of the treatment group of three months (1103.13±640.87pg/ml) was not obviously changed,but still lower than the control group(1549.79±897.79pg/ml.It has statistical significance(P＜0.05).2.The two-group LVEF values the With the changes in clinical symptoms were gradually improved,the treatment 7 days,The LVEF levels of the treatment group(35.37±5.59%) were significantly lower than the control group(32.60±4.12%)(P＜0.05 ).Compared between the treatment group and the control group,the LVEDD levels have not been found to have statistically significant changes(P＞0.05).ConclusionrhBNP(Xin Huo Su) has genuine effect on the treatment of thepatients with acute exacerbation of HF.It is better than conventional drug therapy,short-term ventricular remodeling has not found a clear improvement of results.
|
PDF Full Text Request